FDA clears Pfizer and Moderna's bivalent boosters, seeking to slow the next wave of Omicron
As part of an attempt to halt a likely new surge of hospitalizations and deaths from Omicron’s BA.5 subvariant this fall, the FDA on Wednesday authorized both Pfizer/BioNTech and Moderna’s bivalent boosters, which aim to attack this latest version of the deadly coronavirus, which has taken more than one million lives since March 2020.
But the authorizations of these updated boosters for those 12 and older — which partly includes an mRNA component of the original coronavirus strain from Wuhan, China, and also an mRNA component from the BA.4 and BA.5 lineages — didn’t come with any new human data, leaving critics to question if the new shots are actually more effective at preventing hospitalization or death than the original vaccines from both companies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.